Obstructive sleep apnoea syndrome is common in subjects with chronic bronchitis - Report from the obstructive lung disease in Northern Sweden studies

Citation
Lg. Larsson et al., Obstructive sleep apnoea syndrome is common in subjects with chronic bronchitis - Report from the obstructive lung disease in Northern Sweden studies, RESPIRATION, 68(3), 2001, pp. 250-255
Citations number
33
Categorie Soggetti
Cardiovascular & Respiratory Systems","da verificare
Journal title
RESPIRATION
ISSN journal
00257931 → ACNP
Volume
68
Issue
3
Year of publication
2001
Pages
250 - 255
Database
ISI
SICI code
0025-7931(200105/06)68:3<250:OSASIC>2.0.ZU;2-I
Abstract
Background: In previous studies we have found that subjects with bronchitis have a higher prevalence of 'snoring as a problem' than respiratory health y subjects. Objectives: We aimed to study whether the high prevalence of sn oring among subjects with bronchitis also represents a high prevalence of o bstructive sleep apnoea (OSA). Method: Subjects in three age groups born 19 19-1920, 1934-1935 and 1949-1950 had been identified as bronchitic in an ea rlier study (n = 471) and without respiratory symptoms (n = 108). Of the 91 subjects reporting snoring to be a problem, 70 were invited to participate in the study. Sleep investigation was performed in 52 of these 70 subjects . Results: 'Snoring as a problem', predicted OSA to a similar degree in bot h bronchitic and respiratory healthy subjects. The estimated prevalence for obstructive sleep apnoea with an apnoea/hypopnoea index (AHI) 10 as the cu t-off point and concomitant daytime symptoms such as daytime sleepiness or liability to nodding off during breaks in activity in the daytime, was 5.4% for bronchitic subjects and 2.3% for respiratory healthy subjects. Apnoea in addition to snoring predicted OSA better than did snoring alone. Age cor related significantly with AHI, and OSA was most common in the middle-aged group, 61-62 years old. Conclusion: OSA is twice as common in subjects with chronic bronchitis as in subjects free of pulmonary disease or symptoms. C opyright (C) 2001 S. Karger AG, Basel.